Focused On-demand Library for Interleukin-10 receptor subunit alpha

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for receptors.

Fig. 1. The sreening workflow of Receptor.AI

The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q13651

UPID:

I10R1_HUMAN

Alternative names:

CDw210a; Interleukin-10 receptor subunit 1

Alternative UPACC:

Q13651; A8K6I0; B0YJ27

Background:

Interleukin-10 receptor subunit alpha (IL10RA), also known as CDw210a, plays a pivotal role in immune regulation. As a cell surface receptor for cytokine IL10, it initiates anti-inflammatory functions by limiting tissue disruption during inflammation. The binding of IL10 to IL10RA induces a conformational change, facilitating the assembly of a complex that activates kinases JAK1 and TYK2. These kinases phosphorylate IL10RA, leading to STAT3 activation and the expression of anti-inflammatory genes.

Therapeutic significance:

IL10RA's involvement in Inflammatory bowel disease 28, an autosomal recessive condition characterized by chronic inflammation of the gastrointestinal tract, underscores its therapeutic potential. Targeting IL10RA could offer new strategies for managing Crohn's disease and ulcerative colitis, conditions marked by excessive inflammation. Understanding IL10RA's role could open doors to innovative treatments that modulate the immune response in these debilitating diseases.